UNIGE document Scientific Article
previous document  unige:1865  next document
add to browser collection
Title

Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs

Authors
Fried, Ronald
Monnat, Martine
Seidenberg, André
Oppliger, Robert
Herold, Markus
Isler, Marc
show hidden authors show all authors [1 - 12]
Published in Digestion. 2008, vol. 78, no. 2-3, p. 123-30
Abstract BACKGROUND: Though patients in opiate substitution programs are commonly infected with HCV, due to safety and efficacy concerns, they are rarely treated with interferon and ribavirin. METHODS: In a multicenter study, HCV-infected patients in opiate maintenance treatment programs received 180 microg pegylated interferon-alfa-2a once weekly, plus daily ribavirin for 24 weeks (genotypes 2, 3), or 48 weeks (genotypes 1, 4). RESULTS: Of the 67 patients enrolled, 31 (46%) had HCV genotypes 1 or 4, and 36 (54%) had genotypes 2 or 3. Intent-to-treat analysis showed end-of-treatment virologic response in 75% of patients (81% of genotypes 2 or 3; 65% of genotypes 1 or 4), and a sustained virologic response in 61% of patients (72% of genotypes 2 or 3; 48% of genotypes 1 or 4). Fifteen patients (22%) did not complete the study, in 5 (8%) cases because of severe adverse events. CONCLUSIONS: Drug users with chronic HCV infection, regularly attending an opiate maintenance program in which close collaboration between hepatologists/internists and addiction specialists is assured, can be treated effectively and safely with pegylated interferon-alfa-2a and ribavirin. Treatment results are very similar to those in other patient groups, and thus therapy should also be considered for this population.
Keywords AdultAgedAntiviral Agents/administration & dosageDrug Therapy, CombinationDrug UsersFeasibility StudiesFemaleHepatitis C, Chronic/drug therapyHumansInterferon Alfa-2a/administration & dosageMaleMiddle AgedPolyethylene Glycols/administration & dosageRibavirin/administration & dosageTreatment Outcome
Identifiers
PMID: 19023207
Full text
Structures
Research group Médecine de l'addiction (129)
Citation
(ISO format)
FRIED, Ronald et al. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. In: Digestion, 2008, vol. 78, n° 2-3, p. 123-30. https://archive-ouverte.unige.ch/unige:1865

111 hits

2 downloads

Update

Deposited on : 2009-06-02

Export document
Format :
Citation style :